Thompson Medical's Aspercreme
Executive Summary
Multi-site efficacy study in 300 patients will begin in "early October," firm told FDA. Thompson is seeking to upgrade the OTC topical product's active ingredient, triethanolamine salicylate, to Category I from Category III.